NCT02564900 - Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors | Biotech Hunter

Enrollment

292

Participants

Timeline

Start Date

September 1, 2015

Primary Completion Date

February 1, 2019

Study Completion Date

December 22, 2023

Conditions

Advanced Solid Tumors

Interventions

DRUG

DS-8201a (DP1)

DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.

DRUG

DS-8201a (DP2)

DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.

DRUG

DS-8201a (DP)

DS-8201a (DP) is to be administered via intravenous (IV) dose.

Trial Locations (14)

10065

Memorial Sloan-Kettering Cancer Center, New York

32224

Mayo Clinic, Jacksonville

40202

University of Louisville, Louisville

45229

UC Health Clinical Trials Office, Cincinnati

63110

Washington University School of Medicine, St Louis

92123

Sharp Memorial Hospital, San Diego

02215

Dana Farber Cancer Institute, Boston

77030-3721

University of Texas M. D. Anderson Cancer Center, Houston

Unknown

Aichi Cancer Center Hospital, Aichi

National Cancer Center Hospital East, Chiba

Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima

Kindai University Hospital, Osaka

National Cancer Center Hospital, Tokyo

The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo